• Solventum’s Q3 fiscal 2026 earnings call on November 5 featured CEO Bryan Hanson and CFO Wayde McMillan.
• Adjusted EPS guidance rose to $7.20-$7.30 from $7.10-$7.20; organic sales growth is expected near the top of the 2.5%-3% range.
• Quarterly sales fell 7% to $1.95 billion, reflecting ERP-related order reversals; normalized organic growth was approximately 4%.
• Management is considering a spin-off or sale of Health Information Systems, with approximately 400 basis points of anticipated operating margin dilution.
• A renegotiated 3M supply agreement eliminates a potential 100-basis-point gross margin headwind; management expects operating margin expansion in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Solventum Corporation published the original content used to generate this news brief on November 06, 2026, and is solely responsible for the information contained therein.